IDE Inhibitors
The IDE inhibitors encompass a diverse group of chemicals meticulously designed to modulate the activity of IDE, a key enzyme involved in the degradation of Aβ peptides and other substrates. Lactacystin and Epoxomicin act as direct inhibitors by irreversibly binding to the proteasome, preventing the degradation of misfolded IDE and impeding its normal enzymatic activity. Z-LLNle-CHO acts as a competitive inhibitor, directly binding to the active site of IDE and blocking substrate binding, thereby inhibiting its enzymatic function. In addition to direct inhibition, compounds like GW2580, GNE-3511, and GW5074 exert their effects indirectly. GW2580 disrupts the CSF-1R pathway, which interacts with IDE, leading to reduced IDE activity and impaired clearance of Aβ peptides. GNE-3511 targets the EGFR pathway, influencing IDE indirectly and affecting the clearance of Aβ peptides. GW5074 modulates the ERK pathway, regulating IDE phosphorylation and impacting its enzymatic activity.
Other inhibitors, such as Ro 31-8220, SP600125, VX-745, and JSH-23, exert their effects by disrupting signaling pathways that regulate IDE phosphorylation. Ro 31-8220 inhibits PKC, hindering IDE phosphorylation and impairing its enzymatic activity. SP600125 and VX-745 target the JNK pathway, influencing IDE indirectly by modulating its phosphorylation status. JSH-23 disrupts the NF-κB pathway, which interacts with IDE, leading to reduced IDE activity and impaired clearance of Aβ peptides. In conclusion, the IDE inhibitors offer a sophisticated approach to modulating IDE activity, either directly through active site binding or indirectly by influencing pathways related to its regulation. These chemicals provide valuable tools for researchers seeking to understand and intervene in the processes associated with Aβ peptide accumulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin inhibits IDE directly by acting as a potent and irreversible proteasome inhibitor. This leads to the accumulation of misfolded IDE and prevents its normal enzymatic activity. | ||||||
cFMS Receptor Tyrosine Kinase Inhibitor | 870483-87-7 | sc-203877 sc-203877A | 1 mg 5 mg | $32.00 $54.00 | ||
A CSF-1R inhibitor that indirectly inhibits IDE by disrupting the CSF-1R pathway, which interacts with IDE. Inhibition of CSF-1R leads to reduced IDE activity and impaired clearance of Aβ peptides. | ||||||
Compound E | 209986-17-4 | sc-221433 sc-221433A sc-221433B | 250 µg 1 mg 5 mg | $124.00 $342.00 $967.00 | 12 | |
Compound E is a γ-secretase inhibitor that indirectly inhibits IDE by preventing the generation of Aβ peptides. Reduced Aβ peptides availability diminishes IDE activity, impacting its normal function. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220, a PKC inhibitor, indirectly inhibits IDE by disrupting the PKC pathway, which regulates IDE phosphorylation. Inhibition of PKC hinders IDE phosphorylation and impairs its enzymatic activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin inhibits IDE directly by acting as a potent and irreversible proteasome inhibitor. This leads to the accumulation of misfolded IDE and prevents its normal enzymatic activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly inhibits IDE by disrupting the JNK pathway, which regulates IDE phosphorylation. Inhibition of JNK hinders IDE phosphorylation and impairs its enzymatic activity. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074, an ERK inhibitor, indirectly inhibits IDE by disrupting the ERK pathway, which regulates IDE phosphorylation. Inhibition of ERK hinders IDE phosphorylation and impairs its enzymatic activity. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT, a γ-secretase inhibitor, indirectly inhibits IDE by preventing the generation of Aβ peptides. Reduced Aβ peptides availability diminishes IDE activity, impacting its normal function. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, a JNK inhibitor, indirectly inhibits IDE by disrupting the JNK pathway, which regulates IDE phosphorylation. Inhibition of JNK hinders IDE phosphorylation and impairs its enzymatic activity. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
Also called JSH-23, this compound inhibits IDE indirectly by disrupting the NF-κB pathway, which interacts with IDE. Inhibition of NF-κB leads to reduced IDE activity and impaired clearance of Aβ peptides. | ||||||